People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...

Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and ...

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lily has announced positive topline results from the novel TOGETHER-PsA open-label Phase IIIb trial evaluating ...

With the introduction of the oral version of Wegovy, the weight-loss drugs that have taken the world by storm will become ...

Kim Davis started taking the weight loss drug Zepbound in 2024 and saw success. However, she lost insurance coverage for the ...